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SUMMARY
Purpose: To classify the grade of antiepileptic drug
(AED) resistance in a cohort of patients with focal epi-
lepsies, to recognize the risk factors for AED resistance,
and to estimate the helpfulness of ‘‘new-generation’’
AEDs.
Methods: We included 1,155 adults with focal epilepsies
who were observed consecutively after 1990 and followed
regularly at two epilepsy centers. We systematically col-
lected the clinical, diagnostic, and therapeutic data using a
custom-written database. We classified the patients as
seizure-free or AED resistant according to the Interna-
tional League Against Epilepsy (ILAE) criteria, and we
evaluated the risk factors associated with AED resistance
using logistic regression analysis. We further grouped
AED-resistant patients in different grades (I, II, and III)
according to the number of AEDs already tried as pro-
posed by Perucca.
Key Findings: AED resistance occurred in 57.8% of the 729
patients with symptomatic focal epilepsies and was posi-
tively associated with electroencephalography (EEG)
abnormalities, seizure type, and the presence of mesial
temporal sclerosis. Among 426 patients without detect-
able causes, the percentage of AED resistance was
significantly lower (39.2%) and correlated with EEG
abnormalities and psychiatric symptoms. Among AED-
resistant patients, the majority (64.6%) had tried three or
more AEDs, which fit the more severe grade III proposed
by Perucca. Among seizure-free patients, more than one-
half (57%) needed to try two or more AEDs before reach-
ing seizure control (14.9% needed three or more AEDs).
Furthermore, among seizure-free patients who could be
previously classified as resistant to two or more AEDs,
52.2% reached seizure freedomwhile receiving treatment
with ‘‘new generation’’AEDs.
Significance: The ILAE classification of AED resistance, as
well the graded classification proposed by Perucca, was
easily exploitable in our patients, although these classifica-
tions systems appear to have a limited value in predicting
seizure outcome. Actually, a small but not negligible
percentage of patients reached seizure freedom after try-
ing several AEDs (including ‘‘new’’ AEDs), suggesting
repeated trials may be necessary for seizure control.
KEY WORDS: Focal epilepsy, Antiepileptic drug resis-
tance, Antiepileptic drugs.
Focal epilepsies are the most common forms of epilepsy
in adults and have heterogeneous etiologies and outcomes.
Most of the data relating to the prognosis of focal epilepsies
come from studies of patients who are selected on the basis
of specific inclusion criteria, such as newly diagnosed
patients (Kwan & Brodie, 2000; Mohanraj & Brodie, 2005,
2006; Hitiris et al., 2007), or pathologic conditions (Pittau
et al., 2009; Varoglu et al., 2009). The lack of large case
series means that the published meta-analyses are based on
a limited number of studies of rather small patient popula-
tions.
The outcome of epilepsy depends on various factors,
including the severity of ictal phenomena, the time of occur-
rence, and the possible progression of neuropsychological
defects. A major prognostic factor is the response to antiepi-
leptic drugs (AEDs) (Mohanraj & Brodie, 2005; Schiller &
Najjar, 2008; Schiller, 2009), which in principle seems to be
easily measurable, although the criteria used by different
authors to identify and define AED resistance are heteroge-
neous. The International League Against Epilepsy (ILAE)
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recently activated a task force to study the issue of
AED-resistance and published a Consensus Proposal (Kwan
et al., 2009). This proposal defined ‘‘seizure freedom’’ as
‘‘freedom from seizures for a minimum of 12 months or for
a period lasting three times the longest pre-intervention
inter-seizure interval,’’ and AED resistance as ‘‘the failure
of adequate trials of two tolerated and appropriately chosen
and used AED schedules.’’ However, the Consensus Pro-
posal also underlined the limits of the classification due to
the limited information available concerning long-term
prognosis and the limited information about the risk factors
associated with a poor outcome.
Because the ILAE classification (Kwan et al., 2009) did
not allow specific evaluation of the seizure resistance with
regard to the number of tried AEDs, we also applied the
graded classification proposed by Perucca (1998), in which
the degrees were based on the number of drugs to which a
patient had previously not responded.
We aimed this study to verify the applicability of the
AED-resistance classification and to evaluate the risk fac-
tors for AED resistance in a large cohort of patients with
focal seizures, who were consecutively enrolled and fol-
lowed. Moreover, we evaluated the effectiveness of the
new-generation AEDs that have become available over the
last 20 years and we assessed the contribution of these new
molecules to reducing the proportion of AED-resistant
patients.
Methods
Starting from 1990, we included in a custom written data-
base the information related to all patients who were
observed consecutively at the Epilepsy Centers of the Carlo
Besta Foundation Neurological Institute and San Paolo Uni-
versity Hospital. Among these patients, we included in the
present study all patients with focal epilepsies who were
older than 18 years, observed at least twice between 2006
and 2009. We excluded patients who were noncompliant,
patients with incomplete seizure control whose treatment
was left unchanged for particular reasons, and patients who
underwent epilepsy surgery.
The database was created in Microsoft Access (Micro-
soft, Redmond, WA, U.S.A.) and included information
about family history of epilepsy; previous neonatal, febrile,
or acute seizures; age at seizure onset; the presence of neu-
rologic, psychiatric, and cognitive defects (arbitrarily classi-
fied as mild, moderate, or severe); seizure type; and
pathologic electroencephalography (EEG) and neuroimag-
ing findings.
In accordance with the terminology proposed by the
ILAE (Engel, 2001), the epilepsies due to specific etiologies
consistent with the presentation of seizure/epilepsy were
defined as ‘‘symptomatic,’’ as were those associated with
unequivocal signs of brain damage (including mesial tem-
poral sclerosis [MTS]). All of the other epilepsies were
defined as ‘‘probably symptomatic’’ except those associated
with a family history indicating autosomal transmission that
were defined as ‘‘genetic.’’ Based on these diagnostic crite-
ria, the patients with probably symptomatic epilepsy could
have mild (but not moderate or severe) nonfocal neurologic
signs or mild cognitive impairment, and normal or nonspe-
cific neuroimaging findings.
Seizure types were defined based on the classification
proposed by Engel (2001), and we included patients with
generalized seizures without any obvious focal onset if they
were associated with unambiguous evidence indicating a
focal origin (clinical and imaging or EEG findings).
We collected information about current AED treatment
and all of the AEDs received in the past. We did not include
AEDs that were withdrawn because of possible side effects
or given at an uncertain dosage. In line with the ILAE pro-
posal (Kwan et al., 2009), we grouped the patients as being
seizure-free or AED resistant. Moreover, because the ILAE
classification did not allow for evaluation of the seizure
resistance with regard to the number of tried AEDs, we
applied the graded classification proposed by Perucca
(1998), in which the degree was based on the number of
drugs to which a patient had previously not responded
(Table 1). To evaluate the history of AED resistance, the
same classification was also used to describe the immedi-
ately preceding condition of the patients who were seizure-
free at the time of data analysis.
We labeled as ‘‘new AEDs’’ all of the molecules intro-
duced over the last 20 years that have been available for at
least 3 years: lamotrigine, levetiracetam, felbamate, gaba-
pentin, oxcarbazepine, pregabalin, tiagabine, topiramate,
vigabatrin, and zonisamide.
Statistical analysis
We analyzed the data relating to the population as a
whole by means of univariate analysis using the chi-square
test with Bonferroni correction for multiple comparisons.
All of the risk factors capable of predicting AED resistance
that showed a significant association (p < 0.05) in univari-
ate analysis were investigated by means of multivariate
logistic regression, which was applied separately to the
Table 1. Applied classifications of the response to
AED
Seizure freedoma Seizure-free period longer than 12 months or,
in the case of rare seizures, for a period lasting at
least three times the longest interseizure interval
AED resistancea,b
Grade I Resistance to one primary AED
Grade II Resistance to two primary AEDs used sequentially
(grade IIA) or in combination (grade IIB)
Grade III Resistance to three or more primary AEDs used
sequentially (grade IIIA) or in combination (grade IIIB)
aIn line with the criteria of ILAE classification.
bIn line with grades proposed by Perucca (1998).
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patients with symptomatic and ‘‘probably symptomatic’’
epilepsy.
All of the statistical analyses were carried out using SPSS
statistical software, version 14 (SPSS Inc., Chicago, IL,
U.S.A.), and p-values of <0.05 were considered statistically
significant.
Results
Of the 1,155 enrolled patients (584 female), 824 had
been followed for more than 3 years. According to the cri-
teria of ILAE classification, 567 (49.1%) were seizure-free
and 588 (50.9%) were considered AED resistant. At the
time of our observation, seizure-free and AED-resistant
patients had similar age (45.1 € 16.2 vs. 45.1 € 14.7 years)
and sex distributions (women 50.3% vs. 50.8%). The fol-
low-up duration was also similar (6.7 € 5.0 and 6.4 €
5.1 years). As expected, the number of previously tried
AEDs was lower in the seizure-free group (1.5 € 1.8 and
3.7 € 3.4, p < 0.001).
AED resistance and risk factors
The presence of previous acute seizures; familial epi-
lepsy; neurologic, psychiatric, and cognitive defects; patho-
logic EEG and neuroimaging findings; identified causative
factor; seizures with initial consciousness impairment; mul-
tiple seizure types; and akinetic seizures, all correlated with
AED resistance (Table 2).
Because of our previously defined diagnostic criteria,
there was sufficient information to classify the epilepsy as
symptomatic of an identified cause in 645 patients; a fur-
ther 84 cases showing overt signs of brain damage in the
absence of an identified etiology, were also classified as
symptomatic. Five patients had a family history indicating
an autosomal dominant form of genetic epilepsy, which
was associated with a positive molecular diagnosis in two
cases.
A factor that closely correlated with AED resistance was
the presence of an identified etiology (p < 0.001). Indeed,
AED resistance occurred in 57.8% of the symptomatic
patients and 39.2% of the others. Because of this finding,
and taking into account that many of the associated patho-
logic findings indicating unequivocal brain damage of
specific etiology (e.g., previous acute seizures, severe
neurologic defects, and specific neuroimaging findings), we
separately evaluated these two groups using logistic regres-
sion analysis.
Among the patients with symptomatic epilepsies, the
multivariate analysis indicated that AED resistance was
associated with the presence of pathologic EEG findings
(odds ratio [OR] 2.20, p = 0.011), seizures with initial and
prominent consciousness impairment (OR 1.61,
p = 0.006), multiple seizure types (OR 1.48, p = 0.034),
and tonic–akinetic seizures (OR 2.44, p = 0.031). Among
the patients with probably symptomatic epilepsies, the risk
of AED resistance was significantly lower in those with a
family history of epilepsy (OR 0.51, p = 0.019), whereas it
increased with the presence of epileptiform EEG anomalies
(OR 2.36, p = 0.008) and psychiatric symptoms (OR 1.97,
p = 0.025) (Table 3).
Relationship between AED resistance and specific
etiologies/brain lesions
An evaluation of the relationship between AED resis-
tance and the most frequent etiologies (n > 50, including
mesial temporal sclerosis; MTS) using chi-square analysis
followed by Bonferroni correction showed that only MTS
had a significant association (77%, p < 0.001). The patients
who had experienced a previous vascular accident were at a
significantly lower risk of AED resistance (43.4%,
p = 0.008) than patients with other etiologies for seizures.
Many patients with cortical malformations were AED resis-
tant (67.7%), but the association did not survive Bonferroni
correction (p = 0.089). Figure 1 shows the relationship
between all etiologies and AED resistance. Even the more
malignant causes were associated with a relatively high
percentage of seizure-free patients (23.0% of the patients
Table 2. Main characteristics of the case series and
results of univariate analysis
AED
responsive
(567)
N (%)
AED
resistant
(588)
N (%)
Univariate
analysis v2
(p-value)
Neonatal seizures
Yes 13 (2.2) 19 (3.2) 0.183
Febrile seizures
Yes 37 (6.5) 52 (8.8) 0.140
Acute symptomatic seizures
Yes 14 (2.5) 33 (5.6) 0.016
Family history of epilepsy
Yes 88 (15.5) 65 (11.1) 0.039
Age at seizure onset
>15 years 374 (66.0) 356 (60.5) 0.093
Seizure typea
Early consciousness
impairment
207 (36.5) 264 (44.9) 0.002
Sensory 376 (66.3) 386 (65.6) 0.626
Motor 130 (22.9) 148 (25.2) 0.243
More than one type 144 (25.4) 190 (32.3) 0.010
Tonic–clonic 99 (17.5) 80 (13.6) 0.100
Tonic–akinetic 18 (3.2) 38 (6.5) 0.009
Neurologic defects 139 (24.5) 190 (32.3) 0.001
Psychiatric defects 121 (21.3) 199 (33.8) <0.001
Cognitive impairment 125 (22.0) 210 (35.7) <0.001
Pathologic EEG 482 (85.0) 554 (94.2) <0.001
Positive neuroimaging
(CT or MRI)b
262 (46.2) 334 (56.8) <0.001
Identified causes 308 (54.3) 421 (71.6) <0.001
Significant values are in bold.
aSix hundred sixty-eight patients had more than one seizure type.
bNeuroimaging consisted mainly of one or more MRI (1,002 patients) or
CT scan (130 patients), which revealed clear focal, diffuse or multifocal cere-
bral damage in 52.6%, and uncertain findings in 8.3%.
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with MTS, and 32.3% of those with cortical malforma-
tions).
In addition to the patients with identified etiologies, we
included 84 patients without an identified etiology but with
overt signs of brain damage among the patients with symp-
tomatic epilepsy. In this small group, 32.1% had moderate/
severe neurologic defects, 55.9% had moderate/severe cog-
nitive impairment, and 54.8% had nonspecific neuroradio-
logic findings. Like the other group of symptomatic
patients, this group included a high percentage of AED-
resistant patients (63.1%).
AED treatment in seizure-free patients and those in the
different subclasses of AED resistance
Figure 2 shows the number of AEDs used at the time of
the last observation in the seizure-free and in AED-resistant
patients indicating the difference in the complexity of the
AED regimens in the two groups. Almost two thirds of the
seizure-free patients but only one-third of the AED-resistant
patients were treated with a single drug; furthermore, about
one-third of the AED-resistant patients received three or
more AEDs.
Classification of the response to AEDs
Of the 588 patients who were considered AED resistant,
22.9% were grade I, 27.0% were grade IIB, and 50.1% were
grade IIIB. None of the patient were grades IIA or IIIA,
probably because of the widespread and consistent approach
of tapering one drug only after assessing the sufficient toler-
ability (and efficacy) of the new drug.
Among the 567 patients who were seizure-free, an evalu-
ation of the treatments used before they became seizure-
free, showed that 43.0% achieved seizure control on their
first AED, 24.9% on their second AED (AED resistance
grade I), and 17.2% and 14.9% on their third (grade II) or
subsequent AED (grade III), respectively (Fig. 3).
Considering the population as a whole, 21% became
seizure-free on their first AED, 12.2% on the second, 8.4%
on the third, and 7.3% on their fourth or subsequent AED.
Usefulness of ‘‘new’’ antiepileptic AEDs
The 1,155 patients tried 4,895 AEDs during the study per-
iod; 1,717 were ‘‘new’’ AEDs. At the time of data analysis,
685 patients had tried at least one new AED and 513 (44.4%
Table 3. Risk factors for AED resistance in symptomatic and ‘‘probably symptomatic’’ patients
Symptomatic (N = 729) Probably symptomatic (N = 426)
Multivariate analysis Multivariate analysis
OR (95%CI) p-value OR (95%CI) p-value
Anamnesis
Acute seizures 1.92 (0.95–3.91) 0.071 n.e. n.e.
Familial epilepsy 0.92 (0.57–1.50) 0.740 0.51 (0.29–0.89)a 0.019
Clinical findings
Neurologic defectsb 0.70 (0.48–1.02) 0.067 1.23 (0.48–3.10) 0.668
Cognitive defectsb 1.19 (0.77–1.83) 0.438 1.85 (0.85–4.01) 0.114
Psychiatric symptoms 1.23 (0.82–1.84) 0.315 1.97 (1.09–3.56) 0.025
Diagnostic examinations
Pathologic EEG 2.20 (1.20–4.04) 0.011 2.36 (1.24–4.38) 0.008
Positive neuroimaging 1.03 (0.69–1.53) 0.897 n.e. n.e.
Seizure types
Early consciousness impairment 1.61 (1.15–2.25) 0.006 0.80 (0.51–1.24) 0.308
More than one type 1.48 (1.03–2.12) 0.034 1.16 (0.72–1.87) 0.541
Tonic–akinetic 2.44 (1.07–4.36) 0.031 0.60 (0.10–3.69) 0.585
OR, odds ratio; CI, confidence interval; n.e., not evaluated. Significant values are in bold.
aNegative association.
bMild neurologic defect or cognitive impairment.
Figure 1.
Proportion of AED-resistant patients associated with different
etiologies (DNET, dysembryoplastic neuroepithelial tumors).
Epilepsia ILAE
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of the entire series) were still being treated with at least one
new AED (116 on monotherapy and 397 in combined treat-
ment).
Of these 513 patients, 367 continued to experience sei-
zures and 146 (28.5%) were seizure-free (Fig. 4); this group
included 29 patients treated with a new AED as first choice,
33 with previous grade I, 42 with previous grade IIB, and 42
with previous grade IIIB of drug resistance.
The seizure-free patients treated with a new AED
accounted for 25.5% of all seizure-free patients. In par-
ticular, the use of a new AED seemed to be determinant
in achieving freedom from seizures in 43.2% of the 97
patients previously included in grade IIB and in 50.0%
of the 84 previously included in grade IIIB. Adding
together the patients previously considered resistant to
two or more AEDs, 52.5% became seizure-free while
receiving a new AED.
Discussion
Classification of AED resistance
The classification proposed by Kwan et al. (2009) proved
to be easily practicable in providing information about sei-
zure freedom and AED resistance in a relatively large popu-
lation of adult subjects with focal epilepsies. Therefore, it
seems to be a useful means of identifying ‘‘potentially’’
AED-resistant subjects (Alexandre et al., 2010).
The total percentageof our seizure-free subjects (47.1%) is
considerably lower than that reported in other case series
(Mohanraj & Brodie, 2005; Bauer et al., 2007; Schiller &
Najjar,2008).
Considering the grades of AED resistance proposed by
Perucca (1998), the percentage of patients with the most
severe grade IIIB (32.9%) is in line with those reported by
others using various definitions of AED resistance (Regesta
& Tanganelli, 1999; Genton, 2004; Beleza, 2009) and with
that previously observed by us in a larger series of adults
with focal epilepsies attending tertiary centers (OREp
Lombardy, 1996). Therefore, this percentage probably cor-
responds to the percentage of actually difficult to treat
patients, whereas lower grades (I and II) of AED resistance
can be useful to group the patients with still undefined
response to medical treatment.
Figure 3.
Different grades of current and previous AED resistance in
patients who were still AED resistant and those who were sei-
zure-free at the time of data analysis.
Epilepsia ILAE
Figure 4.
Response to treatment schedules including new AEDs.
Epilepsia ILAE
Figure 2.
Current AED schedules of seizure-free and AED-resistant
patients.
Epilepsia ILAE
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Almost half of the seizure-free patients achieved seizure
freedom with their first AED, which suggests that there is a
large subpopulation of patients with naturally ‘‘benign’’ and
easy-to-treat focal seizures. This percentage is lower than
that reported by others (Shorvon et al., 1978; Richens et al.,
1994; Heller et al., 1995; Mohanraj & Brodie, 2005), who
found that more than two thirds of the patients become
seizure-free on their first AED. However, most of these
included patients with generalized epilepsies (which are
probably more susceptible to being controlled), whereas we
included only patients with focal epilepsies. The low per-
centage of patients achieving seizure freedom on their first
AED may also be due to the considerable proportion of
patients with severe epilepsies referred to epilepsy centers.
Of interest, a relatively large number of patients achieved
seizure freedom after trying more than two AEDs; indeed,
14.8% of the patients in grade IIIB became seizure-free, a
percentage that is definitely higher than the <5% reported
by Perucca (1998) but similar to that reported by Schiller
and Najjar (2008) in patients with different forms of epi-
lepsy, most of whom had focal epilepsy. This nonnegligible
percentage suggests that even the grade III proposed by
Perucca (1998) could be not sufficient to consider a patient
putatively unresponsive to any medical treatment. This find-
ing is in line with the observation of Luciano & Shorvon
(2007) and Callaghan et al. (2007), who reported a similar
percentage of seizure remission in a population of adult
patients with various seizures types, previously considered
as AED resistant. A more complex algorithm, including not
only the number of tried AEDs, but also other risk factors,
might be a more effective approach to evaluate AED resis-
tance. Indeed, it seems that the failure of one or two AEDs
can be considered a predictor of AED resistance only in the
presence of associated risk factors (such as MTS or cortical
malformations), whereas in other patients it is worth consid-
ering further AED trials.
Risk factors for AED resistance
Because the presence of a specific etiology correlated
closely with AED resistance, we evaluated symptomatic
and probably symptomatic focal epilepsies separately. Our
definition of ‘‘probably symptomatic’’ agrees with that pro-
posed by Engel (2001) for epilepsies without any detectable
anatomic or dysfunctional factor, and generally overlaps the
concept of cryptogenic epilepsy. The latest proposals of the
ILAE task force (Berg et al., 2010) recommend defining
symptomatic epilepsy based on its specific etiology because
epilepsy inevitably has a causative factor, an approach that
avoids equivocal definitions. However, in our experience,
this leaves more than one-third of patients with focal sei-
zures (probably with still undetectable structural lesions or
genetic determinants) in a sort of penumbra if even the
detailed diagnostic workup used in dedicated centers is
unable to identify a specific etiology. However, this ‘‘pen-
umbra’’ seems to have a provisional value, as it allows the
identification of a subpopulation with a more benign prog-
nosis (at least in terms of AED resistance) than those with
identified etiologies. Moreover, it can be expected that at
least some of these patients will be identified as having a
new genetic disorder, possibly inherited by means of non-
autosomal (or nonmonogenic) transmission.
In our ‘‘symptomatic’’ patients, AED resistance corre-
lated positively with the presence of multiple seizure types
and types that seldom occur in focal epilepsies, such as tonic
or atonic seizures that are known to be often refractory to
medical treatment (So, 1995; Tassinari et al., 2008). This
association likely also indicates that complex or multiple
epileptic neuronal networks are highly refractory to AEDs.
Moreover, AED resistance correlated with the presence
of `seizures with early or prominent consciousness impair-
ment, thus suggesting an origin in cortical regions that are
more likely to generate ictal discharges that are difficult to
control.
Among the epilepsy-associated brain lesions, MTS sig-
nificantly correlated with AED-resistance as reported previ-
ously in other case series (Semah et al., 1998; Stephen
et al., 2001; Pittau et al., 2009; Varoglu et al., 2009). How-
ever, our findings also indicated the presence of a minority
of patients with a ‘‘benign’’ prognosis, as reported by Labate
et al. (2006). As suggested by the finding of Semah et al.
(1988) and Varoglu et al. (2009), associated risk factors
may influence the risk of a bad prognosis.
A considerable proportion of our patients with cortical
malformations, another etiology that often sustains severe
epilepsies (Bartolomei et al., 1999; Semah & Ryvlin, 2005)
were seizure-free. Our inclusion criteria (adult patients with
clear focal seizures) probably influenced the percentage of
patients achieving seizure freedom.
Among the ‘‘probably symptomatic’’ subjects, the posi-
tive relationship between AED resistance and psychiatric
pathologies can be interpreted as a reactive condition in
patients whose seizures are constraining in the absence of
any significant neurologic or cognitive defects (Beghi et al.,
2002; Modrego et al., 2002).
Of interest, the inverse relationship between a family
history of epilepsy and AED resistance suggests that, even
in the absence of a clear ‘‘genetic’’ picture (found in only
five of our patients), the ‘‘probably symptomatic’’ group
includes a percentage of patients with relatively benign
genetically determined epileptic syndromes.
Pathologic EEG findings correlated significantly with
AED resistance in both the symptomatic and probably
symptomatic patients, as has been found in most case series
in which the relationship was evaluated, mainly patients
with newly diagnosed epilepsies (see review by Sander &
Sillanpaa, 2008), whereas pathologic imaging findings did
not. This underlies the importance of ‘‘dysfunctional’’ cor-
tices, which can be detected clearly using neurophysiologic
methods but are less consistently detectable by means of
‘‘anatomic’’ techniques.
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AED treatments
Treatment approach
The evaluation of previous and current medical treat-
ments revealed a high number of treatment changes involv-
ing ‘‘old’’ and ‘‘new’’ AEDs, which suggests that the
neurologists treating our patients had a dynamic therapeutic
approach. Nevertheless, the treatment schedules were sim-
ple, as the current pharmacologic therapies included only
one AED for most seizure-free patients and almost one third
of the AED-resistant patients. This suggest that the centers
treating our population consider a treatment regimen based
on the lowest possible number of AEDs to be optimal for
reducing side effects and drug interactions.
The usefulness of ‘‘new’’ AEDs
We included the antiepileptic molecules that have
become available over the last 20 years, including those that
are tapered mainly because of the risk of idiosyncratic or
long-term side effects, such as felbamate and gabapentin
(Leppik, 1995; Krauss et al., 1998; Perucca, 2002). We also
included AEDs the pharmacologic spectra of which are sim-
ilar to those of the ‘‘old’’ AEDs, but which have pharmaco-
kinetic advantages or are better tolerated, such as
oxcarbazepine (Schmidt & Elger, 2004). Our data are there-
fore unsuitable for comparatively evaluating the effective-
ness of different AEDs, which is in any case beyond the
scope of the study. Moreover, given that data collection
stopped 2 years ago, we probably underestimated the use of
more recently introduced AEDs.
While bearing these limitations in mind, the new AEDs
seem to be extensively used, as more than half of our
patients had tried one or more new AEDs, and one-third of
them were still being treated with these drugs at the time of
our last observation.
The percentage of patients becoming seizure-free on a
‘‘new’’ AED was small but worthy of note. Those with a
history of grade II or grade III AED resistance accounted
for 46.4% of all the patients achieving complete seizure
control. This suggests that, together with the development
of the more rational use of all AEDs over the last few
decades that the discovery of new molecules provides a
real opportunity for patients with still-resistant focal epi-
lepsies, particularly given the multiple limitations of a
surgical approach.
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